Bruce E. Sands
#110,296
Most Influential Person Now
American gastroenterologist
Bruce E. Sands's AcademicInfluence.com Rankings
Bruce E. Sandsphilosophy Degrees
Philosophy
#4609
World Rank
#7193
Historical Rank
Logic
#2028
World Rank
#2924
Historical Rank
Download Badge
Philosophy
Bruce E. Sands's Degrees
- Bachelors Biology University of Pennsylvania
Similar Degrees You Can Earn
Why Is Bruce E. Sands Influential?
(Suggest an Edit or Addition)According to Wikipedia, Bruce E. Sands is an American gastroenterologist, focusing in colonoscopy, Crohn's disease, inflammatory bowl disease, ulcerative colitis and upper GI endoscopy, currently the Dr. Burrill B. Crohn Professor of Medicine at Mount Sinai School of Medicine and is an Elected Fellow of the American College of Gastroenterology and American Gastroenterological Association.
Bruce E. Sands's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Infliximab for induction and maintenance therapy for ulcerative colitis. (2005) (2903)
- Infliximab for the treatment of fistulas in patients with Crohn's disease. (1999) (2254)
- Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment (2012) (2091)
- Infliximab maintenance therapy for fistulizing Crohn's disease. (2004) (2059)
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) (1847)
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) (1815)
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target (2015) (1329)
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial (2012) (1245)
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) (1026)
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) (945)
- Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011) (803)
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults (2018) (732)
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) (611)
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
- Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. (2005) (581)
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) (573)
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020) (529)
- Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
- Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. (2009) (488)
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2019) (472)
- Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. (2009) (464)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (440)
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011) (435)
- Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study (2001) (432)
- From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. (2004) (338)
- Reliability and initial validation of the ulcerative colitis endoscopic index of severity. (2013) (332)
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. (2019) (329)
- LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens (2010) (328)
- Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. (2004) (323)
- Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. (1993) (280)
- Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. (2008) (273)
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium (2016) (250)
- Biomarkers of Inflammation in Inflammatory Bowel Disease. (2015) (250)
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017) (248)
- Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and ROR&ggr;t+ Regulatory T Cells and Exacerbate Colitis in Mice (2019) (241)
- Inflammatory bowel disease: past, present, and future (2007) (238)
- Guidelines for immunizations in patients with inflammatory bowel disease. (2004) (231)
- Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications (2008) (227)
- American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. (2007) (226)
- Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. (2016) (224)
- The trefoil peptide family. (1996) (222)
- Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease (2016) (219)
- The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association (2010) (218)
- 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy (2012) (217)
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease (2012) (208)
- Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies (2012) (207)
- A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. (2008) (206)
- Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. (1999) (201)
- Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. (2008) (200)
- Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study (2010) (200)
- Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. (2015) (188)
- Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. (2007) (184)
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. (2017) (182)
- A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. (2006) (177)
- Long-term Efficacy of Vedolizumab for Ulcerative Colitis (2016) (168)
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. (2019) (167)
- Long-term Efficacy of Vedolizumab for Crohn’s Disease (2016) (164)
- Functionally defective germline variants of sialic acid acetylesterase in autoimmunity (2010) (158)
- Risk of early surgery for Crohn's disease: implications for early treatment strategies (2003) (152)
- Therapy of inflammatory bowel disease. (2000) (150)
- The Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis (2008) (145)
- Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. (2000) (139)
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy (2017) (138)
- Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease (2002) (137)
- Risks and benefits of infliximab for the treatment of Crohn's disease. (2006) (137)
- Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease (2004) (134)
- Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. (2018) (133)
- Abatacept for Crohn's disease and ulcerative colitis. (2012) (130)
- Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab (2007) (130)
- Review article: practical management of inflammatory bowel disease patients taking immunomodulators (2005) (126)
- The Role of TNFα in Ulcerative Colitis (2007) (125)
- Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease (2017) (119)
- Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study (2006) (117)
- Outcome of Surgical Versus Percutaneous Drainage of Abdominal and Pelvic Abscesses in Crohn's Disease (2006) (116)
- Occurrence of Colon Ischemia in Relation to Irritable Bowel Syndrome (2004) (115)
- Possible Association Between Isotretinoin and Inflammatory Bowel Disease (2006) (114)
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme (2019) (113)
- Gut microbiota density influences host physiology and is shaped by host and microbial factors (2018) (110)
- Validation of the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) in patients with inflammatory bowel disease (2011) (110)
- The DUNE Far Detector Interim Design Report Volume 1: Physics, Technology and Strategies (2018) (110)
- Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy (2018) (108)
- Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial (2003) (106)
- Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity (2014) (105)
- Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (105)
- Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease (2011) (97)
- Transition of Adolescents With Inflammatory Bowel Disease From Pediatric to Adult Care: A Survey of Adult Gastroenterologists (2009) (96)
- IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (2019) (96)
- Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus (2018) (95)
- Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease. (2020) (94)
- Prevention and treatment of osteoporosis in inflammatory bowel disease (2006) (93)
- Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis (2007) (92)
- Development of an index to define overall disease severity in IBD (2016) (92)
- State of the Art: Ibd Therapy and Clinical Trials in Ibd (2005) (86)
- Risk Factors for Colon Ischemia (2004) (85)
- The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark (2007) (84)
- Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease (2010) (82)
- Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. (2010) (81)
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study (2018) (80)
- IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 ‐ Inflammatory bowel disease task force meeting (2011) (80)
- Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies (2017) (80)
- A Survey of Current Practice of Venous Thromboembolism Prophylaxis in Hospitalized Inflammatory Bowel Disease Patients in the United States (2013) (77)
- Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. (2018) (77)
- Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease (2011) (73)
- Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (2008) (72)
- The role of TNFalpha in ulcerative colitis. (2007) (68)
- Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. (2020) (64)
- Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease (2020) (62)
- Post Hoc Analysis (2022) (61)
- Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial (2015) (59)
- Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease (2020) (57)
- Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. (2018) (56)
- Long‐term safety of vedolizumab for inflammatory bowel disease (2020) (55)
- Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species (2003) (54)
- Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. (2018) (54)
- Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride (2003) (53)
- Risk factors for colorectal cancer in Crohn's colitis: A case‐control study (2006) (53)
- Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open (2019) (53)
- When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations (2008) (53)
- A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease (2012) (51)
- Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. (2012) (51)
- The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. (2015) (51)
- Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease (2017) (49)
- Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. (2019) (49)
- Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. (2016) (48)
- A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. (2016) (47)
- 415a – Anti-Tumor Necrosis Factor Therapy is Not Associated with Post-Operative Infection: Results from Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Postoperative Infection I (Puccini) (2019) (47)
- Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. (2019) (47)
- The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] (2015) (47)
- Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study (2015) (46)
- A Survey of Methodological Variation in the Crohn's Disease Activity Index (2005) (46)
- The DUNE Far Detector Interim Design Report, Volume 3: Dual-Phase Module (2018) (45)
- Erratum: Identification of human intestinal trefoil factor. Goblet cell- specific expression of a peptide targeted for apical secretion (Journal of Biological Chemistry (1993) 268 (6694-6702)) (1993) (45)
- Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort (2019) (45)
- Review article: medical therapy for fistulizing Crohn's disease (2006) (44)
- Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients? (2009) (44)
- Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with Crohn's Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study (2013) (44)
- SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. (2014) (44)
- Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. (2015) (44)
- Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease (2008) (43)
- O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFN&agr;: UNITI-1 (2016) (43)
- Efficient augmentation and relaxation learning for individualized treatment rules using observational data (2019) (43)
- Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. (2018) (43)
- 960 Exposure to Anti-TNFα Therapy in the Third Trimester of Pregnancy Is Not Associated With Increased Adverse Outcomes: Results From the PIANO Registry (2014) (42)
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies (2020) (42)
- Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. (2019) (42)
- Design Issues and Outcomes in Ibd Clinical Trials (2005) (42)
- Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial. (2021) (42)
- High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. (2015) (42)
- Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. (2012) (42)
- Characterization of patients with infliximab‐induced lupus erythematosus and outcomes after retreatment with a second anti‐TNF agent (2011) (41)
- Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? (2011) (39)
- Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? (2006) (39)
- Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? (2011) (38)
- Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases. (2019) (38)
- 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial (2012) (38)
- Mo1194 Anti-TNFα Therapies Are Safe During Pregnancy in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2014) (37)
- 1 Achievement of Developmental Milestones Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry (2014) (37)
- Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. (2017) (37)
- Novel therapies for inflammatory bowel disease. (1999) (36)
- Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease (2006) (36)
- Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease (2020) (36)
- Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. (2013) (35)
- Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis (2019) (35)
- Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States (2014) (35)
- Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis (2020) (34)
- 437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry (2016) (34)
- Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. (2022) (33)
- Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. (2020) (33)
- Biologic Therapy for Inflammatory Bowel Disease (1997) (33)
- Efficacy of methotrexate in ulcerative colitis: Failure or promise (2010) (33)
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial (2022) (33)
- Effects of growth hormone secretion on body composition in patients with Crohn's disease. (2003) (32)
- Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. (2019) (32)
- Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. (2018) (32)
- New life in a sleeper: thalidomide and Crohn's disease. (1999) (32)
- Selective leukocyte apheresis for the treatment of inflammatory bowel disease. (2007) (31)
- Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. (2018) (31)
- Anti-TNF&agr; Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2014) (31)
- Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (2020) (31)
- An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. (2021) (30)
- Why do anti-tumor necrosis factor antibodies work in Crohn's disease? (2004) (30)
- Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy (2020) (29)
- Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation (2006) (29)
- OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study (2021) (29)
- Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis (2015) (28)
- Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature (2013) (28)
- Menstrual Cycle Changes in Women with Inflammatory Bowel Disease: A Study from the Ocean State Crohn's and Colitis Area Registry (2014) (28)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial (2011) (28)
- OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis (2019) (27)
- Molecular Cloning of the Rat Intestinal Trefoil Factor Gene (1995) (27)
- Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study (2017) (27)
- Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study (2021) (27)
- Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
- Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1 (2018) (27)
- Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. (2020) (26)
- Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease (2015) (26)
- Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study (2015) (25)
- Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
- Colorectal cancer in Crohn’s colitis is comparable to sporadic colorectal cancer (2016) (24)
- Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure (2021) (24)
- 970 Risk of Lymphoma Associated with Anti-TNF Agents for the Treatment of Crohn's Disease: A Meta-Analysis (2008) (24)
- Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis. (2020) (23)
- Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity (2022) (23)
- Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors (2015) (23)
- New Therapeutics for Ulcerative Colitis. (2021) (22)
- 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials (2016) (22)
- The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease (2010) (22)
- Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. (2021) (22)
- Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. (2019) (21)
- Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents (2010) (21)
- Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers (2017) (21)
- Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis (2020) (21)
- Validation of interactive voice response system administration of the short inflammatory bowel disease questionnaire (2008) (21)
- Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522 (2012) (20)
- 830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study (2015) (20)
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. (2021) (19)
- 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease (2019) (19)
- Epidemiology of inflammatory bowel disease and overview of pathogenesis. (2009) (19)
- Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry (2016) (19)
- New Drugs on the Horizon for IBD (2014) (18)
- The day after COVID-19 in IBD: how to go back to ‘normal’ (2020) (18)
- 768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI (2016) (18)
- Acute appendicitis following colonoscopy. (2005) (18)
- A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease (2019) (17)
- Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease. (2019) (17)
- There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center (2016) (17)
- New therapies for the treatment of inflammatory bowel disease. (2006) (16)
- Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence (2016) (16)
- Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies (2018) (16)
- Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (16)
- A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease. (2019) (16)
- OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years (2017) (16)
- 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study (2021) (16)
- Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease (2020) (15)
- The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions and the general population. (2020) (15)
- OSCCAR: Ocean State Crohn's and Colitis Area Registry. (2009) (15)
- Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3 (2019) (15)
- Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions (2017) (15)
- Integrative analysis of the Inflammatory Bowel Disease serum metabolome improves our understanding of genetic etiology and points to novel putative therapeutic targets. (2021) (15)
- Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments (2020) (14)
- Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2022) (14)
- Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. (2020) (13)
- Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data (2020) (13)
- The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease (2018) (13)
- Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility (2022) (13)
- OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis (2018) (13)
- Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence. (2019) (12)
- Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study (2017) (12)
- Medical therapy of steroid-resistant Crohn's disease. (2000) (12)
- SAFETY AND ACTIVITY EVALUATION OF rhlL‐11 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE.: 520 (1997) (12)
- OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. (2017) (12)
- OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study (2019) (12)
- Fulminant Colitis (2008) (12)
- 11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial (2013) (12)
- Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. (2018) (12)
- Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults. (2018) (12)
- Risk factors for radiation exposure in newly diagnosed IBD patients (2016) (12)
- Biological therapies for ulcerative colitis. (2001) (11)
- 416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis (2019) (11)
- Novel Non-biologic Targets for Inflammatory Bowel Disease (2019) (11)
- Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: O‐1b (2012) (11)
- DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open (2018) (11)
- 649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) (2010) (11)
- 14 POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION (2018) (11)
- OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis (2018) (10)
- 643 Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (10)
- Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management (2020) (10)
- Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: P‐27 (2012) (10)
- Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot? (2015) (10)
- 855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial (2016) (10)
- Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials (2016) (10)
- DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. (2017) (10)
- Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542 (2012) (10)
- Testing for Clostridium difficile in Patients Newly Diagnosed with Inflammatory Bowel Disease in a Community Setting (2015) (10)
- Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium (2017) (10)
- A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS (2019) (10)
- High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. (2022) (10)
- Rosiglitazone for Active Ulcerative Colitis (2009) (10)
- Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. (1993) (10)
- Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease≥100 points (2003) (10)
- Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn’s Disease: 1618 (2014) (9)
- Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-2 Study. (2022) (9)
- Critical Evaluation of Current Concepts and Moving to New Horizons in the Management of IBD: Falk Symposium 196, Frankfurt, March 2015 (2015) (9)
- Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State: 1200 (2010) (9)
- Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. (2015) (9)
- Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients (2017) (9)
- Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2: O-006. (2008) (9)
- Exposure to Biologic Therapy and Childhood Development among Offspring of Women with Inflammatory Bowel Disease: Results from the Piano Registry (2017) (9)
- Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy (2021) (9)
- P513 Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo-controlled, double-blind, multi-centre trial (2013) (8)
- Sa1761 - Efficacy and Safety of Dose Escalation to Tofacitinib 10 Mg Bid for Patients with Ulcerative Colitis Following Loss of Response on Tofacitinib 5 Mg Bid Maintenance Therapy: Results from Octave Open (2018) (8)
- A Randomized, Placebo-Controlled Trial of the PPARγ Ligand Rosiglitazone for Active Ulcerative Colitis (2007) (8)
- Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility (2021) (8)
- Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients with Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. (2022) (8)
- Results from a beam test of a prototype PLT diamond pixel telescope (2011) (8)
- Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients (2016) (8)
- When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease? (2018) (8)
- Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes (2019) (8)
- Within you, without you: is gastroenterology ready to embrace the "exposome"? (2012) (8)
- Crohn's disease and IL-10 therapy: promise regained. (2003) (7)
- 277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (7)
- T1153 Infliximab Treatment for Ulcerative Colitis: Comparable Clinical Response, Clinical Remission, and Mucosal Healing in Patients with Disease Duration < 3 Years Vs ≥ 3 Years (2008) (7)
- DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial (2019) (7)
- P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study (2018) (7)
- Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) (2021) (7)
- The Risks and Benefits of Early Immunosuppression and Biological Therapy (2013) (7)
- Ileocolic anastomotic inflammation after resection for Crohn’s disease indicates disease recurrence: a histopathologic study (2020) (7)
- Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial) (2022) (7)
- 764 One Year Newborn Outcomes Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry (2010) (7)
- Sa1123 Infusion-Related Reactions With Vedolizumab Treatment in Patients With UC or CD During the GEMINI 1 and GEMINI 2 Clinical Trials (2015) (7)
- Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. (2021) (7)
- Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. (2020) (7)
- Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study (2020) (7)
- P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (2013) (6)
- 865 Phase IIB, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Ulcerative Colitis (2014) (6)
- 562 A Multi-Center National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy (2009) (6)
- Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohnʼs Disease Treated with Vedolizumab: 1676 (2013) (6)
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply. (2020) (6)
- The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis (2019) (6)
- Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases (2022) (6)
- ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. (2022) (6)
- Treatment of ulcerative colitis. (1999) (6)
- P213 Influence of clinical history on scoring of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (6)
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (6)
- Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2: 984 (2007) (6)
- OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI (2016) (6)
- OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study (2021) (5)
- The Single-Phase ProtoDUNE Technical Design Report : arXiv (2017) (5)
- Ustekinumab Dose Intensification Can Be Effective in Crohnʼs Disease Patients Not Responding to Induction (2018) (5)
- Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments: 607 (2017) (5)
- P068 MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2020) (5)
- Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (2022) (5)
- Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years (2018) (5)
- Tu1849 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2020) (5)
- Babesiosis in a patient on infliximab for Crohn's disease. (2010) (5)
- Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease (2016) (5)
- P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (5)
- P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease (2012) (5)
- P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years (2019) (5)
- Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial. (2022) (5)
- Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients: The ACT Trials (2005) (5)
- T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) (2008) (5)
- Tu1724 – Association of Ustekinumab Serum Concentrations and Perianal Fistula Resolution in the Crohn's Disease Uniti Program (2019) (5)
- Dietary behaviors in newly diagnosed youth with inflammatory bowel disease (2017) (5)
- P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme (2018) (5)
- Comment on ‘Anti-Adhesion Therapies and the Rule of 3 for Rare Events’ (2014) (5)
- DOP023 Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials (2018) (4)
- Biopsy and blood-based molecular biomarker of inflammation in IBD (2022) (4)
- Ocean State Crohn's and Colitis Area Registry (OSCCAR) (2011) (4)
- A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY (2018) (4)
- Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1 (2020) (4)
- PILOT STUDY ON THE SAFETY AND EFFICACY OF GRANULOCYTE/MONOCYTE ADSORPTION APHERESIS WITH ADACOLUMN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 811 (2004) (4)
- Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension. (2021) (4)
- S777 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials (2021) (4)
- 1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2009) (4)
- 904 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 4.4 Years of Safety Data from Global Clinical Trials (2019) (4)
- HealthPROMISE: Utilization of Patient Reported Outcomes to Measure Quality of Life in Inflammatory Bowel Disease (2017) (4)
- Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study (2018) (4)
- Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials. (2022) (4)
- Maintenance infliximab is safe and effective in fistulizing Crohn’s Disease(CD); results from the accent II trial (2002) (4)
- Sa1273 Efficacy and Safety of Retreatment With Vedolizumab in Patients With Crohn's Disease (2015) (4)
- Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti‐TNF Antagonist Failure: A Randomized, Placebo‐controlled, Double‐blind, Multicenter Trial: P‐26 (2012) (4)
- S0703 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials (2020) (4)
- Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebo-controlled trial (2016) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (4)
- Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program (2021) (4)
- Practices, attitudes, and knowledge about Crohn’s disease and smoking cessation among gastroenterologists (2018) (4)
- Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy: 570 (2016) (4)
- The Effectiveness of Continuing the Induction Dose of Asacol into the Maintenance Phase: Results from the Community Setting (2005) (4)
- Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years (2017) (4)
- P057 IMPROVED QUALITY OF CARE AND QUALITY OF LIFE FOR IBD PATIENTS USING MOBILE BASED REMOTE MONITORING PLATFORM: A RANDOMIZED CONTROL TRIAL (2018) (4)
- 1039 Natalizumab Reduces the Hospitalization Rate in Moderate to Severe Crohn's Disease Patients: A Pooled Analysis of the ENACT-1 and ENCORE Studies (2008) (4)
- Biologic agents: data in adults and children. (1998) (3)
- P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies (2019) (3)
- DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study (2020) (3)
- Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open (2022) (3)
- Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. (2012) (3)
- Decreased fertility after restorative proctocolectomy (2002) (3)
- Natalizumab reduces the rate of hospitalization in moderate to severe Crohnʼs Patients: Evidence from the Clinical Trial Program: P-0068. (2009) (3)
- Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (3)
- The Incidence of Influenza and Influenza-related Complications in Inflammatory Bowel Disease Patients across the United States: 1833 (2013) (3)
- Efficacy of Ustekinumab for Ulcerative Colitis Through 2 Years: Results of the UNIFI Maintenance Study and Long-term Extension (2020) (3)
- Biologicals: principles, techniques and mechanisms of action. (2001) (3)
- Maintenance of Quality of Life Improvement in a Phase 3 Study of Tofacitinib for Patients with Moderately to Severely Active Ulcerative Colitis (2017) (3)
- S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study (2020) (3)
- OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2 (2016) (3)
- 17 - Improved Quality of Care and Quality of Life for IBD Patients using Healthpromise App: A Randomized, Control Trial (2018) (3)
- Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium: 1904 (2015) (3)
- Response to Letter by Field et al, Influenza Vaccinations: Should They Really be Encouraged for IBD Patients Being Treated with Immunosuppressives? (2009) (3)
- Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY (2021) (3)
- OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1 (2016) (3)
- Women's Preferences for IBD Medical Therapy during Pregnancy (2017) (3)
- P390 Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study (2018) (3)
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply. (2020) (3)
- M1231 Functional Assessment of Chronic Illness Therapy-Fatigue (Facit-F) Scale is Valid in Patients With Inflammatory Bowel Disease (2010) (3)
- 389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis (2009) (3)
- Impact of Real World Home-Based Remote Monitoring on Quality of Care and Quality of Life in IBD Patients: Interim Results of Pragmatic Randomized Trial (2017) (3)
- Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: O‐1a (2012) (3)
- Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home (2021) (3)
- S0705 Evaluation of Symptom Improvement During Induction in Patients With Crohn's Disease Treated With Mirikizumab (2020) (3)
- Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. (2022) (3)
- Inflammatory bowel disease microbiotas alter gut CD4 T-cell homeostasis and drive colitis in mice (2018) (2)
- Personalized Medicine with IL-23 Blockers: Myth or Reality? (2021) (2)
- Micronutrients and Their Role in Inflammatory Bowel Disease: Function, Assessment, Supplementation, and Impact on Clinical Outcomes Including Muscle Health. (2022) (2)
- Tu1723 – Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease (2019) (2)
- Stress and gut inflammation: The perception becomes reality (2001) (2)
- DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis (2018) (2)
- P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019 (2020) (2)
- Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments: 709 (2016) (2)
- Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium (2016) (2)
- Sa1272 Efficacy and Safety of Retreatment With Vedolizumab in Patients With Ulcerative Colitis (2015) (2)
- S0683 Absence of Bowel Urgency Is Associated With Improvements in Clinical Outcomes in Patients With Ulcerative Colitis Receiving Mirikizumab (2020) (2)
- S1232 The TOUCH™ Program and Risk Management Plan for the Administration of Natalizumab: Lessons and Updated Safety Results from the Use of Natalizumab in Patients with Relapsing Multiple Sclerosis and Implications for Potential Use in Crohn's Disease (2008) (2)
- S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study (2021) (2)
- DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial (2018) (2)
- 190 Functional Aspects of the Intestinal Microbiome in Inflammatory Bowel Disease (2012) (2)
- P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension (2020) (2)
- A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis: ACT I Trial Results through Week 54 (2005) (2)
- OP17 A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies (2019) (2)
- Long-Term Safety in the Open-Label Period of a Phase 2a Study of Brazikumab, an Antibody Against Interleukin-23 (2018) (2)
- Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium (2017) (2)
- Gastroenterologists’ Tolerance for Crohnʼs Disease Treatment Risks: 1020 (2007) (2)
- Ocean State Crohnʼs and Colitis Area Registry (OSCCAR): Incidence of Crohnʼs Disease and Ulcerative Colitis in a Prospective, Population-Based Inception Cohort in Rhode Island: 1172 (2010) (2)
- Biologics in Fistulizing Crohn’s Disease: So Near, Yet So Far (2011) (2)
- 258 Validation of Simplified Stricture Severity Score (4S) to Predict the Need for Surgery in Patients With Stricturing Crohn's Disease (2014) (2)
- Tu1739 – Efficacy and Safety of Ustekinumab Through Week 16 in Patients with Moderate to Severe Ulcerative Colitis Randomized to Ustekinumab: Results from the Unifi Induction Trial (2019) (2)
- SMAD 3 gene variant is a risk factor for recurrent surgery in patients with Crohn ' s disease (2014) (2)
- Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials (2021) (2)
- Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 2 Years (2018) (2)
- DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis (2018) (2)
- P-016 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis (2016) (2)
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (2023) (2)
- 689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial (2019) (2)
- 764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study (2019) (2)
- DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity (2020) (2)
- Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium difficile Patients With and Without IBD (2018) (2)
- DOP054 Vedolizumab in combination with steroids for induction therapy in Crohn’s disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studies (2018) (2)
- 132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE (2021) (2)
- Sa1761 AN INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH INCREASED CLINICAL REMISSION RATES AND LOWER STEROID USE (2020) (2)
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023) (2)
- Variation in Treatment of Patients with Inflammatory Bowel Diseases at Major US Referral Centers (2015) (2)
- Tu1270 Hygiene Factors in India and the US in Early Childhood Influence the Subsequent Development of Crohn's Disease but Not Ulcerative Colitis: A Large Case Controlled Study in Two Countries (2012) (2)
- Funding and Grantsmanship (2005) (2)
- The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium (2022) (2)
- 328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster: 1227 (2011) (2)
- Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
- Tu1717 – Tofacitinib for the Treatment of Ulcerative Colitis: Up to 5.4 Years of Safety Data from Global Clinical Trials (2019) (2)
- The Whys and Hows of Fourth-Year Inflammatory Bowel Disease Fellowships (2017) (2)
- Toward new questions in inflammatory bowel disease in 1995 (1996) (2)
- Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION (2020) (2)
- 835 – Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results from the Gemini Lts Study (2019) (2)
- Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice (2016) (2)
- Variation in Severity Assessment and Initial Mesalamine Dose Selection for Ulcerative Colitis in Community Practice (2006) (2)
- P186 Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials (2018) (2)
- Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
- Mo1867 - Shorter Disease Duration is Associated with Higher Response Rates to Vedolizumab in Crohn's Disease but not Ulcerative Colitis: A Multi-Center Consortium Analysis (2018) (2)
- Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. (2017) (2)
- P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension (2020) (2)
- 1108 A Prediction Tool to Help Children with Crohn's Disease and Their Parents Understand Individualized Risks of Disease Complications and Response to Therapy (2009) (2)
- Measurement of CP-Violating Asymmetries in B 0 Decays to CP Eigenstates The B A B AR Collaboration (2008) (2)
- 832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies (2019) (2)
- 864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive (2014) (2)
- Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice (2016) (1)
- Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies (2019) (1)
- Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohn’s Disease Treated with Mongersen (GED-0301) (2017) (1)
- Infliximab Reduces UC-Related Hospitalizations Requiring High-Dose Corticosteroids: 1052 (2006) (1)
- P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52 (2020) (1)
- Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease (2019) (1)
- Tu1288 Different Environmental Influences are Associated With the Development of IBD in India Compared to the US: A Case Controlled Study (2012) (1)
- P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study (2021) (1)
- Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II trial (2003) (1)
- Infliximab vs. Adalimumab for Crohn's disease: authors' reply (2008) (1)
- Sa1777 - Combined Clinical and Biological Response (Concomitant Crp and Fecal Calprotectin Reductions) in Induction and Maintenance from the Phase 3 Ustekinumab Crohn's Disease Studies (2018) (1)
- Infliximab does not result in increased, abscess development in fistulizing Crohn's disease: Results from ACCENT II (2003) (1)
- Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment (2012) (1)
- P360 Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity (2019) (1)
- Mucosal Healing Is Associated With Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis Presidential Poster: 1953 (2015) (1)
- 690 Ustekinumab Maintained Clinically Meaningful Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease: Results From the IM-UNITI Long-Term Extension (2019) (1)
- Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohnʼs Disease: Results From Three Phase 3 Clinical Trials (2018) (1)
- Fr549 IMPACT OF MULTI-DISCIPLINARY IBD SPECIALTY CLINIC CARE ON OUTCOMES IN IBD PATIENTS INSURED BY MEDICAID (2021) (1)
- Patient Perceptions of the Risks and Benefits of Infliximab for the Treatment of Inflammatory Bowel Disease: 1120 (2006) (1)
- S0787 An Update on the Analysis of Non-Melanoma Skin Cancer in the Tofacitinib Ulcerative Colitis Clinical Program as of May 2019 (2020) (1)
- New biologic agents: A critical appraisal (1999) (1)
- LRRK2 is an Interferon-gamma Target Involved in Immune Responses (2010) (1)
- Tu1718 – Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the Im-Uniti Study (2019) (1)
- Tu1955 Fecal Calprotectin Reductions in Patients With Mucosal Healing During Vedolizumab Induction Therapy in GEMINI 1 (2016) (1)
- Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION (2020) (1)
- Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. (2021) (1)
- Steroid Sparing Results in Further Improvement in Quality of Life in UC Patients in Remission: 1042 (2006) (1)
- Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD (2018) (1)
- Response to infliximab in fistulizing Crohn's disease is independent of baseline number of draining fistulas (2003) (1)
- 1019 Perioperative Treatment with Infliximab (IFX) in Patients with Crohn's (CD) and Ulcerative Colitis (UC) Is Not Associated with Increased Rate of Postoperative Complications (2008) (1)
- Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond. (2019) (1)
- IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
- Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis (2022) (1)
- Integrated Safety Analyses of Tofacitinib in Ulcerative Colitis Clinical Trials: 731 (2017) (1)
- P525 Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre (2018) (1)
- Crohn's Disease: Clinical Course and Complications (2010) (1)
- Risk of early surgery in Crohn's disease: Implications for early treatment strategies (2001) (1)
- Sa1773 - Methotrexate is not Superior to Placebo in Maintaining Remission in Patients with Ulcerative Colitis -Results from the Merit-Uc Study (2018) (1)
- Mo1359 Early Hospital Readmissions Among Patients With Inflammatory Bowel Disease in the United States (2013) (1)
- 749 Medication Use and Comorbidities Among Elderly as Compared to Younger Patients With Inflammatory Bowel Disease in the TARGET-IBD Cohort (2019) (1)
- Correction to: Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort (2020) (1)
- Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply (2020) (1)
- ASCA positivity is associated with increased risk for early surgery in Crohn's disease (2003) (1)
- 611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE (2021) (1)
- DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial (2020) (1)
- Tu1994 Documentation of IBD Quality of Care and Psychosocial Metrics Among Patients With IBD: Baseline Analysis of Ongoing Pragmatic Randomized Controlled Trial (2016) (1)
- DOP79 Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials (2019) (1)
- 885: TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL (2022) (1)
- Tu1855 EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONGTERM EXTENSION STUDY (2020) (1)
- DOP076 A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis. (2017) (1)
- P388 Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative Colitis (2021) (1)
- Mo1811 - Post HOC Analysis of the Impact of Ustekinumab Treatment on Specific Items of the Inflammatory Bowel Disease Questionnaire in the Uniti-1 & 2 Programs (2018) (1)
- Clinical features of inflammatory bowel disease (1998) (1)
- P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies (2018) (1)
- S0682 Absence of Bowel Urgency Is Associated With Significantly Improved Inflammatory Bowel Disease Related Quality of Life in a Phase 2 Trial of Mirikizumab in Patients With Ulcerative Colitis (2020) (1)
- Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD (2021) (1)
- Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION (2020) (1)
- Fistulizing Crohn’s disease: the aggressive approach (2008) (1)
- Lloyd F. Mayer, MD, June 21, 1952 – September 5, 2013 (2013) (1)
- GM-CSF: Does It Work and How Does It Work? (2006) (1)
- 334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis (2019) (1)
- Therapeutic Targets for Emerging Biologic Therapies in IBD (2009) (1)
- PD-007 YI High-dose Infliximab Lowers 30-Day Colectomy Rates in Hospitalized Ulcerative Colitis Patients: A Propensity-Score Weighted Analysis (2017) (1)
- The Impact of Crohnʼs Disease on Workforce Participation and Productivity in the Workplace and Household: 1137 (2006) (1)
- Tu1879 EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH USTEKINUMAB IN MODERATE-SEVERE ULCERATIVE COLITIS PATIENTS WITH DELAYED RESPONSE TO USTEKINUMAB INDUCTION: RESULTS FROM THE UNIFI 2-YEAR LONG-TERM EXTENSION (2020) (1)
- 950 Addressing Unmet Needs of Inflammatory Bowel Disease Patients With Patient-Reported Outcomes App: A Mixed Methods Study (2015) (1)
- S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension (2020) (1)
- Sa1750 - The Effect of Tofacitinib on Serum Lipids and Cardiovascular Safety in Patients with Ulcerative Colitis - Results from the Tofacitinib Ulcerative Colitis Clinical Program (2018) (1)
- Sa567 A COMPREHENSIVE INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION (2021) (1)
- Personalised Medicine with IL-23 Blockers: Myth or Reality? (2021) (1)
- Improvement in health related quality of life in infliximab-treated moderate-tosevere active ulcerative colitis patients: Improvement overall and by baseline disease activity: O-0019. (2007) (1)
- High-dose Infliximab in Crohnʼs Disease: Clinical Experience, Safety, and Efficacy: 1675 (2013) (1)
- Presenting Symptoms in Inflammatory Bowel Disease: Analysis of a Community-Based Inception Cohort (2018) (1)
- DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort (2020) (1)
- P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis (2020) (1)
- P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study (2019) (1)
- P317 Characterisation of patients with delayed response to ustekinumab for Crohn’s disease (2019) (1)
- Mark Warren Babyatsky, MD (June 29, 1959-August 25, 2014). (2014) (1)
- Mo1908 Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalized Ulcerative Colitis Patients (2016) (1)
- 558 Influence of Symptom Knowledge and History on Disease Scoring With the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (1)
- DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2021) (1)
- IBD: Medical Management (2011) (1)
- S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study (2021) (1)
- 764 MACHINE LEARNING IDENTIFIES NOVEL BLOOD PROTEOMIC PREDICTORS OF PENETRATING AND STRICTURING COMPLICATIONS IN NEWLY DIAGNOSED PEDIATRIC CROHN'S DISEASE (2020) (1)
- Defining Patient-Centered Outcomes for IBD and an International, Cross-Disciplinary Consensus (2017) (1)
- Mount Sinai Expert Guides: Gastroenterology (2014) (1)
- What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment? (2018) (1)
- S16 Association of Quality of Life With Clinical Remission, HEMR, and Bowel Urgency in Patients With Ulcerative Colitis Treated With Mirikizumab (2022) (1)
- Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS (2020) (1)
- Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's diseaseP-39. (2011) (1)
- P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study (2021) (1)
- 857 Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study (2019) (1)
- P034 EFFICACY OF USTEKINUMAB IN CROHN’S DISEASE AT MAINTENENCE WEEK 56: IM-UNITI STUDY (2019) (1)
- Analysis of Non-Melanoma Skin Cancer in the Ulcerative Colitis Program for Tofacitinib (2018) (1)
- Mo1270 Body Image Dissatisfaction in an Incident Cohort of Inflammatory Bowel Disease: A Longitudinal Study From the Ocean State Crohn's and Colitis Area Registry (2013) (1)
- Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease (2021) (1)
- 884a: THE IDEAL STUDY: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL α4β7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (2022) (1)
- Su1793 - Outcomes of Maintenance Ustekinumab Therapy for Crohn's Disease Based on Inflammatory Burden: A Post-HOC Analysis of the Uniti Trials (2018) (1)
- DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease (2018) (0)
- Sa1015 – High Smoking Cessation Rates in a Pharmacist-Led Clinic Embedded in an IBD Center (2019) (0)
- Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohnʼs Disease Patients: Results from the IM-UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663 (2016) (0)
- A Pooled Safety Analysis from the Ustekinumab Crohnʼs Disease and Psoriatic Diseases Phase 2 and 3 Clinical Trial Programs: 2016 ACG Presidential Poster Award: 662 (2016) (0)
- Practices, Attitudes, and Knowledge About Crohnʼs Disease and Smoking Cessation Among Gastroenterologists: 666 (2016) (0)
- Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12 (2022) (0)
- Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB (2021) (0)
- S0815 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease (2020) (0)
- Response to Ribaldone. (2019) (0)
- S3424 Imaging-Negative Double Jejunal Intussusception Diagnosed on Laparoscopy With Intraoperative Enteroscopy in a Patient With Peutz-Jeghers Syndrome (2022) (0)
- Mo1702 Menstrual Function in an Incident Cohort of IBD: A Study From the Ocean State Crohn's and Colitis Registry (2012) (0)
- A Pilot Study on the Effects of Smoking Cessation on Intestinal Gene Expression and the Microbiome: 725 (2016) (0)
- Clinical Vignettes/Case Reports — Inflammatory Bowel Disease (Abstracts 2038-2101) (2018) (0)
- Infliximab, Adalimumab and Certolizumab: Beneficial and Adverse Effects (Present) (2006) (0)
- 642 Effects of Ustekinumab Maintenance Therapy on Endoscopic Improvement and Histologic Improvement in the UNIFI Phase 3 Study in Ulcerative Colitis (2019) (0)
- 813 Immediate Versus Tailored Immunoprophylaxis After Surgery for Crohn's Disease (CD) (2009) (0)
- Impact of Care in an Interdisciplinary Inflammatory Bowel Disease Specialty Clinic on Outcomes in Patients Insured with Medicaid. (2022) (0)
- Cost-Effectiveness of Natalizumab in Patients with Crohnʼs Disease Who Have Failed Anti-TNFα Therapy: 1025 (2008) (0)
- Natalizumab Reduces the Rate of Hospitalization in Moderate to Severe Crohnʼs Patients: Data from the ENACT and ENCORE Trials: 1258 (2009) (0)
- PD-009 A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC (2017) (0)
- S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease (2022) (0)
- Presenting Symptoms at Diagnosis of Crohn's Disease and Ulcerative Colitis (2011) (0)
- M1098 The Serum Metabolome in Inflammatory Bowel Disease (2009) (0)
- Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis (2023) (0)
- S0768 Early and Durable Symptom Control in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod (APD334) in the Phase 2 OASIS Trial and Open Label Extension (2020) (0)
- Infliximab Improves Quality of Life in UC Regardless of Baseline Disease Activity: 1043 (2006) (0)
- 715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program (2019) (0)
- A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease. (2023) (0)
- S0766 An Interdisciplinary IBD Center Improves Adherence to Care in IBD Patients With Medicaid (2020) (0)
- Abstracts (1940) (0)
- P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease (2019) (0)
- Tu1856 THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - UPDATED RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM (2020) (0)
- Real Life Experience With the Use of Ustekinumab for the Treatment of Inflammatory Conditions of the Ileal Pouch (2018) (0)
- Sa1873 OBJECTIVE DISEASE ACTIVITY ASSESSMENT AND THERAPEUTIC DRUG MONITORING IS LACKING PRIOR TO BIOLOGIC THERAPY CHANGES IN ROUTINE INFLAMMATORY BOWEL DISEASE CLINICAL PRACTICE: TARGET-IBD (2020) (0)
- Sa650 DIGITAL NAVIGATION FOR COLONOSCOPY: AN AUTOMATED INTERVENTION TO DECREASE COLONOSCOPY NO-SHOWS (2021) (0)
- S17 Treatment Patterns Among Moderate-to-Severe Ulcerative Colitis Patients in TARGET-IBD (2022) (0)
- Etiology and Pathogenesis of Inflammatory Bowel Disease (2003) (0)
- Inflammatory Bowel Diseases (1998) (0)
- Runs in the family (2003) (0)
- Low Rate of Clostridium difficile Infection Testing in Patients with Newly Diagnosed Inflammatory Bowel Disease and Diarrhea: 1631 (2012) (0)
- Support for suppositories (2001) (0)
- Reply to Letter to the Editor of Dr. Lai and Colleagues. (2019) (0)
- S716 Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study (2022) (0)
- Sa1792 PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES WITH VEDOLIZUMAB VERSUS ADALIMUMAB TREATMENT OF ULCERATIVE COLITIS: RESULTS OF THE VARSITY TRIAL (2020) (0)
- P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
- P-017 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis (2016) (0)
- 697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis (2019) (0)
- S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study (2021) (0)
- S786 Psychometric Evaluation of PROMIS-Fatigue Short Form Scales in Patients With Moderately to Severely Active Crohn’s Disease (2021) (0)
- Tu1238 Body Image Dissatisfaction in an Incident Cohort of Inflammatory Bowel Disease: A Study From the Ocean State Crohn's and Colitis Area Registry (2012) (0)
- P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme (2021) (0)
- Tu1854 MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF RESISTANCE AND ULCERATIVE COLITIS DISEASE ACTIVITY (2020) (0)
- S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12 (2022) (0)
- P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis (2019) (0)
- Sa1765 PERCEPTION OF REMISSION AND PREFERENCE FOR DISEASE SYMPTOMS IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A DISCRETE CHOICE EXPERIMENT (2020) (0)
- Making sense of antisense therapy for murine inflammatory bowel disease (2002) (0)
- 716 Early Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
- Infliximab Therapy Reduces Hospitalizations in Ulcerative Colitis Patients: 847 (2005) (0)
- Sa1881 A COMPARISON OF EARLY RESPONSE PARAMETERS TO INFORM A TREAT-TO-TARGET APPROACH IN ULCERATIVE COLITIS (2020) (0)
- S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study (2022) (0)
- Women’s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy (2021) (0)
- P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies (2019) (0)
- DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis (2019) (0)
- Searching for the crystal ball that will predict response to infliximab (2003) (0)
- Tu1802 - Disease Demarcation in Ulcerative Colitis is Associated with Different Patterns of Gene Expression (2018) (0)
- Late Breaking Abstracts Submitted to DDW 2007 These abstracts were presented at Digestive Disease Week ® in Washington, (2007) (0)
- 671 An Update on the Analysis of Non-Melanoma Skin Cancer in the Tofacitinib Ulcerative Colitis Program (2019) (0)
- X. Challenges update workgroups (2008) (0)
- Subject Index Vol. 32, Suppl. 1, 2014 (2014) (0)
- P113 EVALUATION OF THE EFFICACY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS UTILIZING THE MODIFIED MAYO SCORE: DATA FROM THE OCTAVE PROGRAM (2020) (0)
- A Prototype System Dynamics Model to Communicate the Risk of Crohnʼs Disease Complications to Patients and Their Predicted Treatment Response: 1154 (2008) (0)
- P28 Effect of endoscopic disease criteria on endoscopic outcomes in the SEAVUE study (2022) (0)
- Medical therapy of IBD in the first year after diagnosis (2011) (0)
- NSAIDs 1, IBD 1: Recount eagerly awaited (2001) (0)
- W1147 Validation of the Interactive Voice Response System Administration of the Short Inflammatory Bowel Disease Questionnaire (2008) (0)
- 842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI (2019) (0)
- O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials (2022) (0)
- P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study (2020) (0)
- The ABCs of ileal pouch design (2001) (0)
- Mo1537: COMBINATION AUTOLOGOUS STEM CELL TRANSPLANTATION AND VEDOLIZUMAB FOR REFRACTORY CROHN’S DISEASE (2022) (0)
- Collagenous colitis: Budesonide passes the placebo test (2002) (0)
- 684 INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL DEVELOPMENT PROGRAM: AN UPDATE AS OF MAY 2019 (2020) (0)
- Optimal Management of Fistulizing Crohn’s Disease (2017) (0)
- S761 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response (2021) (0)
- Inflammatory Bowel Diseases: Introduction (2005) (0)
- Chronic Volvulus of the Ileal J-Pouch After Total Proctocolectomy and Ileal Pouch-Anal Anastomosis for Ulcerative Colitis (2022) (0)
- Response to Chapman and Jones. (2019) (0)
- Response to Chamberlin and Borody. (2019) (0)
- DOP012 Disease demarcation in ulcerative colitis is associated with different patterns of gene expression (2018) (0)
- Sa1805 – Medication Prescription Patterns in Ulcerative Colitis in a United States Community-Based Inception Cohort (2019) (0)
- Anti-integrin αvβ6 autoantibodies are a novel predictive biomarker in ulcerative colitis (2022) (0)
- Tu1860 ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER USTEKINUMAB INDUCTION OR MAINTENANCE THERAPY WITH 2-YEAR OUTCOMES IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS (2020) (0)
- Regulation of Immunological Tolerance and Autoimmunity by the Enzyme Sialic Acid Acetylesterase (SIAE) (2010) (0)
- Sensitivity, Specificity, and Stability of Seromarkers in a Prospective, Population-based Inception Cohort of Newly-diagnosed Inflammatory Bowel Disease (IBD): 1678 (2013) (0)
- Sa463 VARIATIONS IN BASELINE DISEASE CHARACTERISTICS OF PATIENTS WITH ACTIVE, MODERATE TO SEVERE CROHN'S DISEASE, BY DISEASE LOCATION (2021) (0)
- 280 THIOPURINE USE IN IBD IS ASSOCIATED WITH A STRONG IMPACT ON B CELLS PROVIDING FURTHER EXPLANATION FOR INCREASED EFFICACY OF ITS COMBINATION THERAPY WITH ANTI-TNF. (2020) (0)
- Crohn’s Disease: Advise and Consent (2007) (0)
- A POPULATION-BASED APPROACH TO DIGITAL OUTREACH, TRIAGE, AND MONITORING OF IBD PATIENTS DURING THE COVID-19 PANDEMIC (2021) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: 1130 (2009) (0)
- Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease (2019) (0)
- Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY (2022) (0)
- Cost-effectiveness of Natalizumab in patients with Crohnʼs Disease who have failed TNF-alpha inhibitor therapy: P-0090. (2008) (0)
- 968: TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTEGRATED SUMMARY OF SAFETY DATA FROM THE GLOBAL OCTAVE AND RIVETING CLINICAL TRIALS (2022) (0)
- Low Rate of Clostridium Difficile Infection Testing in Patients With Newly Diagnosed Inflammatory Bowel Disease and Diarrhea: P‐67 (2012) (0)
- Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. (2023) (0)
- Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. (2023) (0)
- Lessons Learned from the Ocean State Crohn's and Colitis Area Registry. (2022) (0)
- A Shot in the Arm for Methotrexate (2001) (0)
- Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply (2020) (0)
- Correction to: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (The American Journal of Gastroenterology, (2018), 113, 9, (1345-1354), 10.1038/s41395-018-0162-0) (2018) (0)
- Impact of Automated Digital Navigation Program on Bowel Preparation Quality and Patient Satisfaction for Colonoscopy: A Comparative Study Across Multiple Sites (2019) (0)
- Mo1262 Female Sexual Function in an Incident Cohort of Inflammatory Bowel Disease: A Longitudnal Study From the Ocean State Crohn's and Colitis Area Registry (2013) (0)
- P-063 Psychosocial Burden Among Patients with IBD: Prospectively Collected Data from 2 Academic Institutions (2016) (0)
- Feasibility and impact of a quality improvement initiative to screen for malnutrition in an Inflammatory Bowel Disease clinic. (2022) (0)
- Shifts in Vedolizumab Utilization Across the United States Are Associated With Improved Outcomes (2018) (0)
- P013 Immunophenotyping of peripheral whole blood from 743 IBD patients identifies patterns of association between immune cell populations and T-cell subsets with disease occurrence, severity and medication use (2018) (0)
- P621 Physician preferences for biologics (originator vs. biosimilar) for the treatment of ulcerative colitis in France, Germany and the UK (2020) (0)
- Approach to Diarrhea (2014) (0)
- P017 Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Colectomy Analysis from ACT1 and ACT2 (2008) (0)
- Su1019 - Adherence and Persistence with Vedolizumab Among Patients with Inflammatory Bowel Disease in an Academic Medical Center (2018) (0)
- Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (2018) (0)
- TOUCH™ Study Patient Outcomes: Workforce Participation, Productivity and the Impact of Natalizumab: 1134 (2009) (0)
- 886: EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDY (2022) (0)
- Lowering the stress of inflammatory bowel disease. (2002) (0)
- Measurement of the branching fraction, and bounds on the CP-violating asymmetries, of neutral B decays to (DD -/+)-D-*+/- RID C-2728-2008 RID C-5223-2009 RID C-5719-2008 RID D-1055-2009 RID A-2675-2009 (2003) (0)
- S0664 Disease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis (2020) (0)
- 102: DISCOVERY AND VALIDATION OF A BLOOD PROTEIN PANEL ASSOCIATED WITH TUMOR NECROSIS FACTOR ANTAGONIST TREATMENT FAILURE IN RECENTLY DIAGNOSED CROHN'S DISEASE (CD) PATIENTS (2022) (0)
- Subject Index Vol. 30, Suppl. 3, 2012 (2013) (0)
- S714 Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-Label Extension (2021) (0)
- Tu1853 SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES IL-17A AND IL-22 IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS THROUGH WEEK 52 (2020) (0)
- S15 Efficacy of Ozanimod in Patients With Ulcerative Colitis Who Were Previously Exposed to Vedolizumab: True North Post Hoc Analysis (2022) (0)
- Mo1479: PERIANAL FISTULA CLOSURE IN PATIENTS RECEIVING USTEKINUMAB: RESULTS FROM THE SEAVUE AND STARDUST TRIALS (2022) (0)
- The Risk of Developing Crohnʼs Disease after an Appendectomy: A Meta-Analysis of Observational Studies (2006) (0)
- Sa1764 PERCEPTION OF REMISSION AND PREFERENCE FOR DISEASE SYMPTOMS IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM A DISCRETE CHOICE EXPERIMENT (2020) (0)
- Tu1440: LONG-TERM CUMULATIVE SAFETY OF USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS (2022) (0)
- Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD (2022) (0)
- Tu1734 – Effect of Vedolizumab on Surgical Rates in Ibd: Post Hoc Analysis from the Gemini Trials (2019) (0)
- Medical therapy of steroid-resistant (2000) (0)
- S875 The Evolution of Clinical Trial Design in Ulcerative Colitis: Interpreting Future Endpoints Based on Post-Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1 (2021) (0)
- Transition to Adult Care (2009) (0)
- Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award (2018) (0)
- S0887 Fecal Calprotectin as a Surrogate Marker of Clinical Remission, Clinical Response, Endoscopic Improvement, and Histo-Endoscopic Mucosal Healing: UNIFI Induction Study (2020) (0)
- P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
- A Decision Analysis to Define the Thresholds at Which the Risks of Combination Infliximab and Azathioprine Therapy Outweigh Its Benefits: 1257 (2009) (0)
- S696 Efficacy of Ustekinumab for Ulcerative Colitis in Patients Through 3 Years: UNIFI Long-term Extension (2021) (0)
- Do all patients with celiac disease and inflammatory bowel disease need dual‐energy X‐ray absorptiometry? (2003) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients: 1135 (2009) (0)
- Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial (2022) (0)
- W1126 Cost-Effectiveness of Natalizumab in Crohn's Disease Patients Who Have Failed Anti-TNF Alpha Therapy (2008) (0)
- A Crohn's repertoire: T cell receptor γδ (2003) (0)
- 1009 - Immunophenotyping of Peripheral Whole Blood from 743 IBD Patients Identifies Patterns of Association Between Immune Cell Populations and T-Cell Subsets with Disease Occurrence, Severity and Medication Use (2018) (0)
- S1202 The Effect of Time, Baseline Activity and Surgery On Crohn's Disease Activity Index (CDAI) Response Definitions to Optimize Treatment Effect Difference (2008) (0)
- A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE (2018) (0)
- P-025 Corticosteroid Use in A Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients (2013) (0)
- The Utility of Genetics in Classifying Ulcerative Colitis and Crohn's Disease Patients (2011) (0)
- S983 Baseline Demographics and Disease Characteristics of Patients With Ulcerative Colitis Who Responded to Vedolizumab at Week 6 (2022) (0)
- Primum non nocere: Is it time to tumble the old pyramid and build a new one? (2003) (0)
- S1044 Natalizumab Use in Patients with Crohn's Disease and Relapsing Multiple Sclerosis: Updated Utilization and Safety Results from the Touch™ Prescribing Program, the Pregnancy Registry, and the Inform and Tygris Studies (2009) (0)
- P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial (2017) (0)
- Sa1665 IMPACT OF ENGAGEMENT WITH DIGITAL NAVIGATION PROGRAM ON REDUCTION IN NO-SHOW AND INCOMPLETE COLONOSCOPY RATE (2020) (0)
- 757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
- VII. Report of medical therapy subcommittee (2008) (0)
- Tu1468: PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE WITH AND WITHOUT PRIOR BIOLOGIC FAILURE DEMONSTRATED IMPROVED CLINICAL OUTCOMES WITH RISANKIZUMAB: RESULTS FROM PHASE 3 INDUCTION AND MAINTENANCE TRIALS (2022) (0)
- Su1529: LONG-TERM OUTCOMES AFTER HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING: RESULTS FROM THE UNIFI STUDY IN ULCERATIVE COLITIS (2022) (0)
- Taking aim ATP. (1996) (0)
- Fr540 THE PHARMACOKINETICS AND IMMUNOGENICITY OF 5 YEARS OF TREATMENT WITH USTEKINUMAB: RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION (2021) (0)
- Sa1888 – Ustekinumab Therapy Induced Clinically Meaningful Improvement and Remission As Measured by the Inflammatory Bowel Disease Questionnaire in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Induction and Maintenance Studies (2019) (0)
- Seronegative Status Is Associated with Less Severe Disease Phenotype in Newly Diagnosed Crohnʼs Disease in the Community: 637 (2016) (0)
- A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS. (2018) (0)
- M1135 When Should Ulcerative Colitis Patients Undergo Colectomy for Dysplasia? Mismatch Between Patient Preferences and Physician Recommendations (2008) (0)
- P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis (2020) (0)
- S0873 Patient and Gastroenterologist Attitudes of Fecal Microbiota Transplantation as a Treatment for Inflammatory Bowel Disease (2020) (0)
- P-114 Quality of Care and Psychosocial Metrics Among Patients with IBD: Initial Analysis of HealthPROMISE App Pragmatic Randomized Controlled Trial (2017) (0)
- Measurement of time-dependent CP asymmetries and the CP-odd fraction in the decay B-0 -> D*+D*- RID C-2728-2008 RID C-5223-2009 RID C-5719-2008 RID D-1055-2009 RID A-2675-2009 (2003) (0)
- SAFETY AND EFFICACY OF NATALIZUMAB IN PATIENTS CONCURRENTLY RECEIVING INFLIXIMAB IN A PHASE 2 STUDY OF ACTIVE CROHNʼS DISEASE: 789 (2004) (0)
- 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY (2022) (0)
- Medical Therapy of IBD in the First Year After Diagnosis: Preliminary Results from the Ocean State Crohnʼs and Colitis Area Registry (OSCCAR): 1175 (2010) (0)
- 620 A MOLECULAR NETWORK SURVEY PREDICTS NICKEL EXPOSURE AS A POTENTIAL ENVIRONMENTAL TRIGGER OF INFLAMMATORY BOWEL DISEASE (2020) (0)
- Mo1370 Incidence and Predictors of Early Readmission in Patients With Severe Ulcerative Colitis: Results From a Tertiary Care Center (2013) (0)
- PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS (2007) (0)
- Defining Remission Using Patient-reported Outcome Components of the Crohnʼs Disease Activity Index: Post-hoc Analyses of Vedolizumab Data from the GEMINI 2 Study: 1865 (2015) (0)
- S789 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease (2021) (0)
- Sa1987 Nutrition and Dietary Behaviors Over Time in Pediatric Inflammatory Bowel Disease (2012) (0)
- 632 - Immunoglobulin A-Coated Bacteria Represent a Unique Subset of the Microbiome in Patients with Newly Diagnosed Inflammatory Bowel Disease (2018) (0)
- Subject Index Vol. 27, Suppl. 1, 2009 (2010) (0)
- Radiation Exposure to the Abdomen and Pelvis in Patients Newly Diagnosed with Inflammatory Bowel Disease: 1719 (2013) (0)
- S14 Duration of Response After Ozanimod Withdrawal: Phase 3 True North Study Results (2022) (0)
- Mo1275 Menstrual Function in an Incident Cohort of IBD: A Longitudinal Study From the Ocean State Crohn's and Colitis Registry (2013) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Crohn's Disease Severity: 1139 (2009) (0)
- 45 – Long-Term Outcomes of In-Utero Exposure to Thiopurines and Biologic Agents in Children of IBD Mothers (2019) (0)
- Sa1776 - Sustained Corticosteroid-Free Remission with Vedolizumab in Moderate-to-Severe Ulcerative Colitis: A Post HOC Analysis of Gemini 1 (2018) (0)
- Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award: 726 (2017) (0)
- 129 SAFETY OF USTEKINUMAB IN IBD: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (0)
- Sa1701 - A Multicenter Cohort Study to Assess the Safety of Vedolizumab for Inflammatory Bowel Disease (2018) (0)
- IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. (2023) (0)
- PGI22 WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS: CROHN'S DISEASE PATIENTS'WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS (2006) (0)
- Tu1749 – Pharmacokinetics and Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Ulcerative Colitis: Results from the Unifi Induction Study (2019) (0)
- PD-003 Female Sexual Function in Inflammatory Bowel Disease: Longitudinal Study Results from the Ocean State Crohn's and Colitis Area Registry (2017) (0)
- Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1: 1638 (2014) (0)
- Nutrition and dietary behaviors in pediatric Inflammatory Bowel Disease: P-64. (2011) (0)
- Tu1712 – Reduction in Inflammatory Biomarkers in a Phase 2 Study of Mirikizumab in the Treatment of Patients with Moderatelyto-Severely Active Ulcerative Colitis (2019) (0)
- P-064 Corticosteroid Use in Patients with Crohn's Disease Initiating Vedolizumab in the Real-World Setting (2017) (0)
- A Recursive Partitioning Based Clinical Prediction Rule for Long Term Response to Infliximab in Patients with Crohnʼs Disease: 1110 (2006) (0)
- Simultaneous measurement of the B-0 meson lifetime and mixing frequency with B-0 -> D(*-)l(+)nu(l) decays RID C-2728-2008 RID C-5223-2009 RID C-5719-2008 RID D-1055-2009 RID A-2675-2009 (2003) (0)
- 748 Ustekinumab Improved Work Productivity in Patients With Moderate to Severe Ulcerative Colitis: Results From the Phase 3 UNIFI Induction and Maintenance Studies (2019) (0)
- S818 An Insight into the Patient’s Perspective of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts: Key Triggers and Symptoms of Flares (2022) (0)
- ADVANCES IN IBD (2019) (0)
- P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis (2020) (0)
- S760 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response (2021) (0)
- Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. (2023) (0)
- S717 The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy (2022) (0)
- Presenting Symptoms at Diagnosis of Crohnʼs Disease and Ulcerative Colitis: Results from the Ocean State Crohnʼs and Colitis Area Registry (OSCCAR): 1174 (2010) (0)
- P209 Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis (2022) (0)
- Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (0)
- P422 Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1 (2018) (0)
- Mo1798 – Inflammatory Microheterogeneity in Uc: Implications for Microscopic Assessment of Disease Activity (2019) (0)
- There is no Difference in Short-Term Colectomy Rate between Infliximab-Exposed and Infliximab-Naïve Hospitalized Ulcerative Colitis Patients (2017) (0)
- Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. (2023) (0)
- Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program (2022) (0)
- 225 PROGNOSTIC VALUE OF FECAL CALPROTECTIN IN BIOLOGIC-TREATED PATIENTS WITH ULCERATIVE COLITIS (2021) (0)
- Su1274 Differential Protein Expression Profiles in Stricturing Crohn's Disease (2015) (0)
- Tu1467: MIRIKIZUMAB-INDUCED UPREGULATION OF COLONIC TRANSCRIPTS CORRELATES WITH IMPROVEMENTS IN STOOL FREQUENCY IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (0)
- O-0004: The TOUCH program and risk management plan for the administration of Natalizumab: Updated safety results from the use of Natalizumab in patients with relapsing Multiple Sclerosis and Crohn's Disease (2008) (0)
- Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY (2022) (0)
- Tu1239 Female Sexual Function in an Incident Cohort of Inflammatory Bowel Disease: A Study From the Ocean State Crohn's and Colitis Area Registry (2012) (0)
- Abstracts (2005) (0)
- 644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program (2019) (0)
- PD-005 Male Sexual Function in Inflammatory Bowel Disease: Longitudinal Study Results from the Ocean State Crohn's and Colitis Area Registry (2017) (0)
- MEDICAL THERAPY OF CROHN ’ S DISEASE : A REVIEW OF RECENT INNOVATIONS — (2006) (0)
- O29 Efficacy and safety of mirikizumab in patients with ulcerative colitis: phase 3 LUCENT-1 study results (2022) (0)
- 410 Characterization and Outcome of Patients With Infliximab Induced Lupus Erythematosus and Retreatment With a Second Anti-TNF Agent (2010) (0)
- Measurement of the Cabibbo-Kobayashi-Maskawa matrix element vertical bar V-ub vertical bar with B -> pe nu decays RID C-2728-2008 RID C-5223-2009 RID C-5719-2008 RID D-1055-2009 RID A-2675-2009 (2003) (0)
This paper list is powered by the following services:
Other Resources About Bruce E. Sands
What Schools Are Affiliated With Bruce E. Sands?
Bruce E. Sands is affiliated with the following schools:
